QIAGEN announces CE marking of T-cell response measuring device

pharmafile | December 2, 2021 | News story | Business Services  

QIAGEN has launched a CE-marked version of its QuantiFEROn SARS-CoV-2 assay, which measures T-cell responses to SARS-CoV-2, and aids in the assessment of immunity in individuals who have received COVID-19 vaccination.

COVID-19 vaccines stimulate the body to produce antibodies and activate T-cells to fight a SARS-CoV-2 infection. Serology tests, which measure the antibodies, generate positive test results after vaccination, but are unable to assess cellular responses. The QuantiFERON SARS-CoV-2 assay combats this, through detecting CD4+ and CD8+ T-cell responses, enabling a more comprehensive assessment of immunity generated by COVID-19 vaccines.

The QuantiFERON SARS-CoV-2 assay is based on QIAGEN’s QuantiFERON interferon gamma release technology, a T-cell assay with ease of use that employs whole blood.

Advertisement

“T-cells provide valuable insights into our immune system’s response to COVID-19,” said Jean-Pascal Viola, Senior Vice President and Head of the Molecular Diagnostics Business Area at QIAGEN. “The more we know about this epidemic, the better equipped the world will be to address this threat that will stay with us. We are excited about our QuantiFERON technology enabling the assessment of immune responses that are crucial for the prevention and management of the disease.”

T-cell response to SARS-CoV-2 declines slower than antibody response, and may indicate how severe the course of an illness triggered by SARS-CoV-2 will be in infected patients, and how immune those are who have recovered many months, possibly even years, after having been infected.

Lina Adams

Related Content

No items found
The Gateway to Local Adoption Series

Latest content